tiprankstipranks
Scholar Rock assumed with an Overweight at Piper Sandler
The Fly

Scholar Rock assumed with an Overweight at Piper Sandler

Piper Sandler analyst Allison Bratzel assumed coverage of Scholar Rock with an Overweight rating and $26 price target. With the company’s lead asset apitegromab having generated "compelling" Phase 2 data, the Phase 3 data in 2024 is "one of the more de-risked upcoming pivotal readouts in the sector," the analyst tells investors in a research note. Given the remaining unmet need for a muscle-directed therapy in spinal muscular atrophy, the firm believes apitegromab represents a blockbuster opportunity and models $1.4B in 2030 revenue.

Published first on TheFly

See today’s best-performing stocks on TipRanks >>

Read More on SRRK:

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100
Bitcoin

Popular Articles